Free tool
FAERS Monitor: Imdelltra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761344 or its brand name (Imdelltra, Tarlatamab-Dlle). Reports on generic versions are filed under their own applications.
Reports
10
Serious
10
100% of reports
Hospitalization
5
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- cytokine release syndrome4
- immune effector cell-associated neurotoxicity syndrome4
- acute respiratory failure2
- dyspnoea2
- fatigue2
- pain2
- adverse event1
- asthenia1
- atrial fibrillation1
- cardio-respiratory arrest1
- cardiomyopathy1
- cardiovascular disorder1
- chest pain1
- chills1
- decreased appetite1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immune effector cell-associated neurotoxicity syndromeSignal | 4 | 1421.4 | 665.0 | 4,344 |
| cytokine release syndromeSignal | 4 | 419.5 | 196.3 | 1,279 |
| acute respiratory failure | 2 | 218.7 | 63.3 | 243 |
| cardiomyopathy | 1 | 142.3 | 22.2 | 35 |
| cardiovascular disorder | 1 | 82.8 | 12.9 | 20 |
| cardio-respiratory arrest | 1 | 50.3 | 7.8 | 12 |
| adverse event | 1 | 22.8 | 3.6 | 5 |
| atrial fibrillation | 1 | 21.6 | 3.4 | 4 |
| chills | 1 | 17.9 | 2.8 | 4 |
| chest pain | 1 | 11.4 | 1.8 | 2 |
| decreased appetite | 1 | 9.1 | 1.4 | 1 |
| dyspnoea | 2 | 7.4 | 2.2 | 6 |
| pain | 2 | 6.8 | 2.0 | 5 |
| asthenia | 1 | 5.6 | 0.9 | 1 |
| fatigue | 2 | 5.4 | 1.6 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.